The U.S. Food and Drug Administration (FDA) has converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.
Researchers from Sanford Burnham have found that a protein known to be active in immune cells is also active inside melanoma cells, helping promote tumor growth, suggesting that targeting this protein with new drugs may deliver a powerful double hit to melanoma tumors.
Short-term human albumin infusion significantly reduced the incidence of hyponatremia and increased the rate of improvement of hyponatremia in hospitalization hepatic cirrhosis patients.
A systematic search of leading databases and registries by Chinese collaborators compared the efficacy of IVIG to routine care for hospitalized COVID-19 patients.
For the first time, Medicare will have the ability to negotiate lower prescription drug prices because of the Inflation Reduction Act, a law that lowers healthcare and prescription drug costs.
The U.S. Department of Health and Human Services has announced a new Office of Family Violence Prevention and Services under the Administration for Children and Families Act.
Two funding opportunities for Certified Community Behavioral Health Clinic expansion, totaling $123.6 million, were made available by the U.S. Department of Health and Human Services.
The U.S. Department of Health and Human Services (HHS) has issued an amendment to the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19.
A new study shows that a personalized messenger RNA (mRNA) cancer vaccine plus the checkpoint inhibitor Keytruda (pembrolizumab) reduced the risk of recurrence or death in people with high-risk advanced melanoma.
The U.S. Food and Drug Administration has amended the emergency use authorizations of the. Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals.
A large clinical trial of Eli Lilly's experimental Alzheimer's medication, donanemab found the drug slowed declines in patients' ability to think clearly and perform daily tasks by more than a third.
The U.S. Food and Drug Administration has approved LITFULO (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata.